Last reviewed · How we verify

Pegloticase with MTX — Competitive Intelligence Brief

Pegloticase with MTX (Pegloticase with MTX) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant uricase (pegylated enzyme). Area: Rheumatology / Gout.

marketed Recombinant uricase (pegylated enzyme) Uric acid (substrate); reduces anti-pegloticase antibodies via MTX immunosuppression Rheumatology / Gout Biologic Live · refreshed every 30 min

Target snapshot

Pegloticase with MTX (Pegloticase with MTX) — Amgen. Pegloticase is a pegylated uricase enzyme that breaks down uric acid into allantoin, while methotrexate (MTX) is added to reduce anti-drug antibody formation and improve tolerability.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pegloticase with MTX TARGET Pegloticase with MTX Amgen marketed Recombinant uricase (pegylated enzyme) Uric acid (substrate); reduces anti-pegloticase antibodies via MTX immunosuppression

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant uricase (pegylated enzyme) class)

  1. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegloticase with MTX — Competitive Intelligence Brief. https://druglandscape.com/ci/pegloticase-with-mtx. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: